LGVN
Longeveron Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 11 ▼ Maxim Group downgrades
- Aug 31 ▲ Short interest falls 86.7% to 226.3K
- Sep 16 ▼ Longeveron announced that its Phase 2b ELPIS II trial of laromestroc…
- Sep 16 FDA: Longeveron Announces Topline Results from ELPIS II Phase 2…
- Sep 16 Trading halt: Trading Halt: LGVN, T1 (News Pending)
- Sep 30 ▲ Short interest falls 50.0% to 106.8K
- Oct 15 ▲ Short interest falls 31.5% to 73.2K
- Oct 26 FDA: Longeveron Announces Updated Results from ELPIS II Phase 2…
- Oct 26 Longeveron announced updated results from its Phase 2b ELPIS II tria…
- Oct 30 ▼ Short interest jumps 114.7% to 157.1K
- Nov 12 ▼ Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on r…
- Nov 12 ▼ Longeveron reported Q3 2026 revenue of $0.1M, down 16% YoY, and a ne…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 4 added (0 new), 1 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$1.500 → −$1.700 over 90 days. 1 up, 1 down in 30 days.
- Short sellersBUILDING
Short interest +114.7% to 157.1K shares. 2.2 days to cover, ≈4.9% of shares.
- TrendRANGE
24% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | DOUBLED | $951.8K |
| VANGUARD FIDUCIARY TRUST CO | DOUBLED | $98.5K |
| NORTHERN TRUST CORP | DOUBLED | $30.4K |
| JONES FINANCIAL COMPANIES LLLP | DOUBLED | $930.00 |
| UBS Group AG | NEAR_EXIT | $4.00 |
| BlackRock, Inc. | DOUBLED | $233.2K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $211.8K |
| HRT FINANCIAL LP | DOUBLED | $123.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2026Price is below the lowest target. Median implies +2762%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| May 11, 2026 | Maxim Group DOWNGRADE | Hold |
| May 4, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 15, 2025 | Roth Capital MAINTAIN | Buy |
| Mar 21, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Mar 3, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Dec 5, 2024 | Roth MKM INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Willard Stephen H Chief Executive Officer Oct 1, 2026 | TAX W/H | $5.1K |
Agafonova Nataliya Chief Medical Officer Oct 1, 2026 | TAX W/H | $7.5K |
Jhaveri Nirav S. Chief Financial Officer Oct 1, 2026 | TAX W/H | $1.9K |
Blass Devin CTO & SVP of CMC Oct 1, 2026 | TAX W/H | $6.5K |
Lehr Paul T General Counsel, Secretary Oct 1, 2026 | TAX W/H | $5.8K |
Ascheim Deborah Director Aug 19, 2026 | AWARD | 36,000 sh |
Agafonova Nataliya Chief Medical Officer Aug 19, 2026 | AWARD | 286,000 sh |
Lehr Paul T General Counsel, Secretary Aug 19, 2026 | AWARD | 286,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.70 | -$1.70–-$1.70 | +2.9% | $900.0K |
| Next Q | -$1.40 | -$1.40–-$1.40 | -21.7% | $500.0K |
| Current FY | -$7.20 | -$7.20–-$7.20 | +7.1% | $1.8M |
| Next FY | -$5.30 | -$5.80–-$4.80 | -7.4% | $2.2M |
Short side
FINRA· Oct 30, 2026| Sep 16, 2026 | Resumption Scheduled | Resumed |
| Aug 26, 2026 | Resumption Scheduled | Resumed |
SecBot reports
17 filings · 5 press releases · 1 bullish · 8 bearish · 8 neutral- BEARISH SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G disclosing a 4.4% passive stake (133,030 shares) in Longeveron Inc., down from a prior position. The filing indicates the asset manager has reduced its holdings below the 5% threshold, following a pattern of institutional exits from the…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 13, 2026
Benjamin Matthew Wall Baggett filed a Schedule 13G disclosing beneficial ownership of 250,000…
Monitor whether Baggett increases his stake or files a 13D, which would signal activist intent. The company's ongoing strategic review with Lucid Capital Markets (sale or merger process) makes this…
- BEARISH 8-KNov 12, 2026
Longeveron reported Q3 2026 revenue of $0.1M, down 16% YoY, and a net loss of $6.1M (improved from…
The strategic review process (sale/merger) is the key catalyst. Monitor for any definitive agreement, additional financing, or FDA meeting outcome. Cash runway into Q1 2027 creates urgency for a…
- BEARISH PRESS-RELEASENov 12, 2026
Longeveron reported Q3 2026 net loss of $6.1M ($1.91 per share) on revenue of $0.1M, missing the…
The strategic review process (potential sale/merger) is the primary catalyst. Monitor for any definitive agreement or financing announcement. The failed HLHS trial and limited cash runway increase…
All LGVN filing & press-release reports (22)
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 13, 2026
- PRESS-RELEASE reportNov 12, 2026
- 8-K reportNov 12, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 5, 2026
- 8-K reportOct 26, 2026
- PRESS-RELEASE reportOct 26, 2026
- 8-K reportOct 14, 2026
- PRESS-RELEASE reportSep 16, 2026
- 8-K reportSep 14, 2026
- 3 reportJul 13, 2026
- 8-K reportJun 5, 2026
- PRESS-RELEASE reportMay 20, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 8, 2026
- EFFECT reportApr 20, 2026
- 8-K reportApr 10, 2026
- S-1 reportApr 10, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 11, 2026
- 8-K reportMar 9, 2026